Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Change in Acquisitions & Divestments (2016 - 2025)

Dexcom (DXCM) has disclosed Change in Acquisitions & Divestments for 16 consecutive years, with $409.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 1.09% to $409.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 billion, a 23.36% decrease, with the full-year FY2025 number at $2.2 billion, down 23.36% from a year prior.
  • Change in Acquisitions & Divestments was $409.6 million for Q4 2025 at Dexcom, down from $466.2 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $1.1 billion in Q1 2024 to a low of $241.8 million in Q1 2022.
  • A 5-year average of $636.5 million and a median of $644.4 million in 2025 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: crashed 69.39% in 2022, then soared 188.5% in 2023.
  • Dexcom's Change in Acquisitions & Divestments stood at $501.0 million in 2021, then skyrocketed by 47.7% to $740.0 million in 2022, then fell by 2.84% to $719.0 million in 2023, then crashed by 43.64% to $405.2 million in 2024, then grew by 1.09% to $409.6 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Change in Acquisitions & Divestments are $409.6 million (Q4 2025), $466.2 million (Q3 2025), and $638.7 million (Q2 2025).